| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8650977 | American Heart Journal | 2018 | 30 Pages |
Abstract
GENETIC-AF is the first randomized trial of pharmacogenetic guided rhythm control, and will test the safety and efficacy of bucindolol compared with metoprolol succinate for the prevention of recurrent symptomatic AF/AFL in patients with HFrEF and an ADRB1 Arg389Arg genotype. (ClinicalTrials.govNCT01970501).
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jonathan P. MD, MHS, Stuart J. MD, William T. MD, Jeff S. MD, Benjamin A. MD, MHS, Hussein R. PhD, Patricia BS, Dirk J. MD, PhD, William H. MD, Michel MD, Stephen B. MD, Inder S. MD, PhD, Christopher PhD, Debra A. MD, Ryan G. MD, Gordon W. MSPH,